Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ107 in Lymphopenic Newly Diagnosed Glioblastoma
NCT04600817Phase 2Active, not recruiting
- Sponsor
- TJ Biopharma
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of efineptakin alfa in glioblastoma (GBM), sponsored by TJ Biopharma. Started Dec 2020; status: active, not recruiting.
02
Drugs
efineptakin alfa
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04600817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04600817.